Patent application number | Description | Published |
20100197740 | Method of Screening Compounds Having Anti-Amyloid Properties - The invention relates to a method of screening compounds having anti-amyloid properties. The method of screening compounds that are capable of dissociating or preventing high-affinity complexes between β-amyloid peptides and nicotinic acetylcholine receptors of human cortical tissues makes it possible to rapidly identify compounds intended for the curative and/or preventive treatment of neurodegenerative diseases, especially Alzheimer's disease. | 08-05-2010 |
20100279996 | NOVEL ANALGESIC THAT BINDS FILAMIN A - A compound, composition and method are disclosed that can provide analgesia. A contemplated compound has a structure that corresponds to Formula I, wherein R | 11-04-2010 |
20100279997 | ANALGESIC THAT BINDS FILAMIN A - A compound, composition and method are disclosed that can provide analgesia. A contemplated compound has a structure that corresponds to Formula A, wherein A, B, X, R | 11-04-2010 |
20100280057 | NOVEL ANALGESIC THAT BINDS FILAMIN A - A compound, composition and method are disclosed that can provide analgesia. A contemplated compound has a structure that corresponds to Formula I, wherein R | 11-04-2010 |
20100280061 | NOVEL ANALGESIC THAT BINDS FILAMIN A - A compound, composition and method are disclosed that can bind to FLNA and provide analgesia. A contemplated compound has a structure that corresponds to Formula I, wherein R | 11-04-2010 |
20110105481 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC - A compound or its pharmaceutically acceptable salt, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within. | 05-05-2011 |
20110105484 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC - A compound, its pharmaceutically acceptable salt, a composition containing the same and method of treatment that can provide analgesia and/or reduce inflammation are disclosed. A contemplated compound has a structure that corresponds to Formula A, wherein G, W, Q, Z, D, E, F, K, Y, d, e, f, k, n, m, and circle B and all R groups are defined within. | 05-05-2011 |
20110105487 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC - A compound or its pharmaceutically acceptable salt, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within. | 05-05-2011 |
20110105547 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC - A compound, its pharmaceutically acceptable salt, a composition containing the same and method of treatment that can provide analgesia and/or reduce inflammation are disclosed. A contemplated compound has a structure that corresponds to Formula A, wherein G, W, Q, Z, D, E, F, K, Y, d, e, f, k, n, m, and circle B and all R groups are defined within. | 05-05-2011 |
20140017698 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT - An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of α7nAChR or TLR4 in a FLNA-captured protein complex or α7nAChR in an Aβ-captured protein complex or α7nAChR-FLNA, or TLR4-FLNA and/or α7nAChR-Aβ | 01-16-2014 |
20140017699 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT - An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of α7nAChR or TLR4 in a FLNA-captured protein complex or α7nAChR in an Aβ-captured protein complex or α7nAChR-FLNA, or TLR4-FLNA and/or α7nAChR-Aβ | 01-16-2014 |
20140018341 | METHOD OF INHIBITING TAU PHOSPHORYLATION - A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. | 01-16-2014 |
20140094482 | BENZAZOCINE-RING COMPOUND INHIBITION OF TAU HYPERPHOSPHORYLATION - A method of inhibiting hyperphosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system a FLNA-binding effective amount of a FLNA-binding benzazocine-ring compound or a pharmaceutically acceptable salt thereof such as a) an opioid receptor antagonist compound or b) a mixed opioid receptor agonist and antagonist (agonist/antagonist) compound, c) an opioid receptor agonist compound or d) an enantiomer of an opioid receptor interacting compound, that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1. The administered compound preferably contains at least four of the six pharmacophores of FIGS. | 04-03-2014 |